Solid Start to Fiscal Year 2025
IFF reported a 3% comparable currency neutral sales growth to $2.8 billion for Q1 2025, driven by strong volume growth across most business segments including Taste, Pharma Solutions, Scent, and Health & Biosciences.
EBITDA and Margin Expansion
Adjusted operating EBITDA increased by 9% on a comparable currency neutral basis to $578 million, with the EBITDA margin rising over 120 basis points to 20.3%, marking the fourth consecutive quarter of margin expansion.
Successful Divestiture of Pharma Solutions
IFF completed the divestiture of its Pharma Solutions segment to Roquette two months ahead of schedule, achieving a net debt to EBITDA ratio below 3 times.
Taste Segment Performance
The Taste segment achieved a 7% year-over-year increase on a comparable currency neutral basis, with strong profitability driven by volume growth, favorable net pricing, and productivity gains.